These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8103158)

  • 1. Tuberculosis and HIV infection.
    Bevilacqua N; Marasca G; Moscati A; Fantoni M; Ricci F; Ortona L
    Lancet; 1993 Sep; 342(8872):677. PubMed ID: 8103158
    [No Abstract]   [Full Text] [Related]  

  • 2. Tuberculosis prophylaxis in HIV infection.
    Trevett A; Temu P; Naraqi S
    P N G Med J; 1993 Sep; 36(3):256. PubMed ID: 8059554
    [No Abstract]   [Full Text] [Related]  

  • 3. Tuberculosis and HIV infection.
    John TJ; Kaur A; Babu PG
    Lancet; 1993 Sep; 342(8872):676. PubMed ID: 8103156
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.
    Pape JW; Jean SS; Ho JL; Hafner A; Johnson WD
    Lancet; 1993 Jul; 342(8866):268-72. PubMed ID: 8101302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis preventive therapy in HIV-infected individuals. A Joint Statement of the WHO Tuberculosis Programme and the Global Programme on AIDS, and the International Union Against Tuberculosis and Lung Disease (IUATLD).
    Wkly Epidemiol Rec; 1993 Dec; 68(49):361-4. PubMed ID: 8292529
    [No Abstract]   [Full Text] [Related]  

  • 6. Tuberculosis and HIV infection.
    Malone JL; Paparello SF; Malone JD; Hill HE; Myers JW; Weiss P
    Lancet; 1993 Sep; 342(8872):677. PubMed ID: 8103159
    [No Abstract]   [Full Text] [Related]  

  • 7. Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.
    Aguado JM; Pulido F; Moreno S
    N Engl J Med; 1997 Dec; 337(23):1696-7; author reply 1697. PubMed ID: 9411240
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.
    Dore GJ; Law MG; Kaldor JM
    N Engl J Med; 1997 Dec; 337(23):1697. PubMed ID: 9411241
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
    Halsey NA; Coberly JS; Desormeaux J; Losikoff P; Atkinson J; Moulton LH; Contave M; Johnson M; Davis H; Geiter L; Johnson E; Huebner R; Boulos R; Chaisson RE
    Lancet; 1998 Mar; 351(9105):786-92. PubMed ID: 9519950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
    Gordin FM; Matts JP; Miller C; Brown LS; Hafner R; John SL; Klein M; Vaughn A; Besch CL; Perez G; Szabo S; El-Sadr W
    N Engl J Med; 1997 Jul; 337(5):315-20. PubMed ID: 9233868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
    Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
    Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans.
    Desvarieux M
    N Engl J Med; 1998 Mar; 338(12):841; author reply 842-3. PubMed ID: 9508639
    [No Abstract]   [Full Text] [Related]  

  • 13. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis.
    Fitzgerald DW; Morse MM; Pape JW; Johnson WD
    Clin Infect Dis; 2000 Dec; 31(6):1495-7. PubMed ID: 11096020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for the identification, investigation and treatment of individuals with concomitant tuberculosis and human immunodeficiency virus infection. Canadian Thoracic Society, the Tuberculosis Directors of Canada and the Department of National Health and Welfare.
    Can Commun Dis Rep; 1992 Oct; 18(20):155-60. PubMed ID: 1291007
    [No Abstract]   [Full Text] [Related]  

  • 15. Isoniazid prevented active tuberculosis in patients with HIV treated with antiretroviral therapy.
    Sacks HS
    Ann Intern Med; 2014 Sep; 161(6):JC12. PubMed ID: 25222412
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventive treatment for tuberculosis in people with HIV.
    Swaminathan S
    Lancet; 2014 Aug; 384(9944):644-6. PubMed ID: 24835843
    [No Abstract]   [Full Text] [Related]  

  • 17. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group.
    Hanson DL; Chu SY; Farizo KM; Ward JW
    Arch Intern Med; 1995 Jul; 155(14):1537-42. PubMed ID: 7605156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans.
    Turner MT
    N Engl J Med; 1998 Mar; 338(12):841-2. PubMed ID: 9508640
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
    Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
    Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid chemoprophylaxis for dual HIV-TB infection: a cautionary tale.
    FitzGerald JM
    Can Commun Dis Rep; 1995 Feb; 21(4):29-32; discussion 32, 35. PubMed ID: 7735192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.